Serum thrombin activatable fibrinolysis inhibitor levels in patients with newly diagnosed multiple myeloma

Balcik O. S., Albayrak M., Uyar M. E., Dagdas S., Yokus O., Ceran F., ...More

Blood Coagulation and Fibrinolysis, vol.22, no.4, pp.260-263, 2011 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 4
  • Publication Date: 2011
  • Doi Number: 10.1097/mbc.0b013e3283442cf9
  • Journal Name: Blood Coagulation and Fibrinolysis
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.260-263
  • Keywords: multiple myeloma, prognostic factors, thrombin activatable fibrinolysis inhibitor, JUGULAR-VEIN THROMBOLYSIS, INCREASED RISK, THROMBOEMBOLISM, TAFI, COAGULATION, THALIDOMIDE, PREVENTION, RESISTANCE
  • Lokman Hekim University Affiliated: No


Multiple myeloma has been associated with the development of thromboembolic events. Thrombin activatable fibrinolysis inhibitor (TAFI) is a carboxypeptidase B-like proenzyme, which potently inhibits fibrinolysis. The purpose of the present study was to assess the TAFI levels in patients with newly diagnosed multiple myeloma. Twenty-seven newly diagnosed multiple myeloma patients (16 women and 11 men) and 27 age-matched healthy individuals (14 women and 13 men) were included in the study. Serum TAFI levels were significantly increased in patients with multiple myeloma (46 ± 13. 3 vs. 36. 6 ± 9.7 μg/ml) compared with healthy individuals. Serum TAFI levels were negatively correlated with serum albumin (CC: -0.453, P < 0.05) and hemoglobin levels (CC: -0.392, P < 0.05) and positively correlated with the β-2 microglobulin levels (CC: 0.524, P < 0.05). In this study, we observed significantly elevated TAFI levels in patients with multiple myeloma and higher serum TAFI levels were suggested to be associated with higher disease stage. With these results, a possible role of elevated TAFI levels in thromboembolic manifestations in the course of multiple myeloma can be suggested. © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.